[Constitutive activation of the ERK-MAP kinase pathway in human tumors].
Hoshino
R
R
Laboratory of Cell Regulation, School of Pharmaceutical Sciences, Nagasaki University.
Kohno
M
M
D017209:Apoptosis / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D005419:Flavonoids / Q000494:pharmacology / Q000627:therapeutic use; D016193:G1 Phase / Q000187:drug effects; D006801:Humans; D020935:MAP Kinase Signaling System / Q000502:physiology*; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000502:physiology*; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology
D004791:Enzyme Inhibitors; D005419:Flavonoids; D020928:Mitogen-Activated Protein Kinases; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one